Graphic featuring a syringe to illustrate an HIV vaccine trial

Innovation-opedia: What is a mosaic vaccine?

As the IAS Conference on HIV Science kicks off in Mexico City, we explain how an investigational HIV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson works—and how researchers hope to help change lives around the world with it.

Written by Johnson & Johnson

| July 22, 2019

July 22, 2019

Illustrated handwritten definition of a mosaic HIV vaccine

Illustration of a microscope with information about Janssen Vaccines & Prevention B.V. investigational HIV-1 vaccine regimen

Inset- Innovation-opedia: What Is a Mosaic Vaccine?- mosaic-vaccine-4-immunizations_above

Illustration of the # 4 explaining how many injections would be administered for Janssen’s investigational HIV-1 vaccine.

Inset- Innovation-opedia: What Is a Mosaic Vaccine?- mosaic-vaccine-4-immunizations_below

Illustration showing location of the IAS Conference on HIV Science with details about Janssen’s new Mosaico clinical trial.

Illustrated quote by Janssen’s Maria Grazia Pau talking about the goal of creating a global HIV vaccine.

We’re committed to helping lead the fight against HIV/AIDS

Read about the many ways Johnson & Johnson is working to #makeHIVhistory.

CTA-Red ribbon HIV

HIV vaccine J&J Innovative Medicine Johnson & Johnson

More from Johnson & Johnson

Innovation

November 13, 2025

Moving toward a more personalized approach to treating depression

The World Health Organization predicts that depression will be the leading cause of disability across the globe by 2030. Learn how Johnson & Johnson is on a mission to change that.

Innovation

November 10, 2025

“Our goal is a solution for every bladder cancer patient”

Meet Christopher Cutie, M.D., the Johnson & Johnson scientist who’s helping change the treatment landscape for people with bladder cancer, the tenth most common cancer in the world.

Health & wellness

November 6, 2025

Is this the end of one-size-fits-all treatments for depression?

Learn how Johnson & Johnson is working to better address the needs of the 7 in 10 people with depression whose treatments aren’t providing enough relief.